Brics and straws

Brics and straws

Brics Bank has its own limitations, and let us hope it will...
Much ado about execution

Much ado about execution

Effective delivery must be brought to the centre of policy-making...

'Neutral' on Sun Pharmaceuticals Industries shares

Jun 14 2013, 01:39 IST
Comments 0
SummarySun Pharmaceuticals Industries announced settlement of the Protonix litigation and agreed to pay $550 million. We believe Sun Pharma earned $400–500 million from the product. This is higher than $300 million that we had factored into our target price and $107 million provisioned for by the company in 2Q13.

Sun Pharmaceuticals Industries announced settlement of the Protonix litigation and agreed to pay $550 million. We believe Sun Pharma earned $400–500 million from the product. This is higher than $300 million that we had factored into our target price and $107 million provisioned for by the company in 2Q13.

The cash outflow is 42% of Sun Pharma’s consolidated cash balance and the incremental liability (over and above provisions made in FY13) is approx 17% of FY13 net worth (we do not assume any tax benefit at this stage).

The potential earnings impact due to one-time extraordinary expense can be R24.5/share in FY14 assuming no tax shield, which is 60% of projected earnings for FY14E. Sun Pharma is trading at 23.8xFY14F and 22.2xFY15F, a 15–20% premium to peers.

We believe one of the key reason for the premium multiple is a strong balance sheet and the possibility of a value accretive acquisition. Therefore, reduction in cash balance could lead to some correction in PE multiples. We have a ‘neutral’ rating on the stock with sum-of-the-parts target price of R842/share, which implies PE multiple of 18.5xFY15 estimates.

Sun Pharma currently trades at 23.8xFY14 and 22.2xFY15 estimates, which is a 15–20% premium to other front-line peers.

Ads by Google

More from Money & Funds

Reader´s Comments
| Post a Comment
Please Wait while comments are loading...